Trial to Reduce IDDM in the Genetically at Risk Study

Information

  • Research Project
  • 6575324
  • ApplicationId
    6575324
  • Core Project Number
    U01HD040364
  • Full Project Number
    3U01HD040364-01S1
  • Serial Number
    40364
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/26/2001 - 23 years ago
  • Project End Date
    6/30/2006 - 18 years ago
  • Program Officer Name
    AKOLKAR, BEENA
  • Budget Start Date
    9/26/2001 - 23 years ago
  • Budget End Date
    6/30/2002 - 22 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
    S1
  • Award Notice Date
    3/26/2002 - 22 years ago
Organizations

Trial to Reduce IDDM in the Genetically at Risk Study

The overall objective of the project is to determine whether weaning to a casein hydrolysate (Nutramigen/Tm) during at least the first 6 months of life reduces the incidence of Type 1 diabetes in genetically susceptible children. Specific Aims: I-a:To determine, if weaning to casein hydrolysate reduces the frequency of diabetes-predictive autoantibodies in subjects with risk-associated HLA genotype and a first degree relative with type 1 diabetes: I-b: To determine, if weaning to casein hydrolysate reduces the frequency of clinical diabetes in subjects with risk-associated HLA genotype and an affected first degree relative. Newborn infants, who have an increased genetic risk and first degree relatives with type 1 diabetes (mother, father or sibling has the disease, and HLA genotyping shows the subject to belong to the increased risk group) will be invited for the study. An international, multicentre, double blink, randomized, controlled trial of two different nutritional supplements will be performed. The newborn infants will be randomly allocated to receive after breast feeding one of two formulas during at least the first 6 months of life (the intervention period). The test formula will be a casein hydrolysate, free of intact cow's milk proteins. The casein hydrolysate is not diabetogenic in the NOD mouse. The control formula will be similar to a commonly used cow milk-based instant formula. Subjects will be followed during and after the intervention period for 6 and 10 years time during which serological markers are measured and the development of diabetes will be recorded. Such a clinical trial is necessary to get a definite answer to the hypothesis. Recruitment is carried out during a 2-year period in the U.S., Canada and 15 other countries. The estimated number of subjects participating in the randomized nutritional prevention study is approximately 2,800. This requires that genetic screening would be performed in approximately 6,200 newborn infants. The study question has important public health implications.

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
  • Activity
    U01
  • Administering IC
    HD
  • Application Type
    3
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    389268
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    999
  • Ed Inst. Type
  • Funding ICs
    NICHD:389268\
  • Funding Mechanism
  • Study Section
    CHHD
  • Study Section Name
    National Institute of Child Health and Human Development Initial Review Group
  • Organization Name
    UNIVERSITY OF HELSINKI
  • Organization Department
  • Organization DUNS
  • Organization City
    HELSINKI
  • Organization State
  • Organization Country
    FINLAND
  • Organization Zip Code
    00014
  • Organization District
    FINLAND